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ABSTRACT 
Int J Exerc Sci 4(2) : 141-151, 2011. The use of caffeine-containing (74-mg) energy patches (EnP) 
offers a novel mode of caffeine delivery that may alleviate stomach discomfort associated with 
oral caffeine use.  The purpose of this study was to use four separate tests to evaluate the effects 
of EnP use on aerobic and anaerobic exercise performance.  Three separate moderately active 
college-aged sample populations performed either 1) cycle time-to-exhaustion (n = 9), 2) Wingate 
(WIN; n = 13), or 3) repeated sprints and one repetition maximum bench press (n = 10) using EnP 
and placebo patches (PlP).  No statistical differences were found between EnP and PlP for all 
dependent variables (p > 0.05) except for WIN peak power, which showed a statistically 
significant decrease (p = 0.04).  The dose of caffeine topically applied via an EnP may not have 
been enough to elicit an ergogenic effect on exercise performance.  A dose of caffeine greater than 
74-mg may be needed to produce an ergogenic effect.  Further research is needed to investigate 
the delivery kinetics of transdermal caffeine in large dosages along with blood caffeine 
concentrations during and after exercise. 
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INTRODUCTION 
 
The effects of orally ingested caffeine on 
exercise performance have been well 
documented since Costill et al. (10) initially 
proposed caffeine’s ergogenic effect on 
endurance cycling.  Caffeine has shown 
obvious increases in laboratory-based 
endurance tests.  Graham and Spriet (14) 
showed increases of 44.3 and 52.3% for 
elapsed time at exhaustion (ET) for run and 
cycle time-to-exhaustion (TTE) tests at 80% 
maximal oxygen consumption (VO2MAX), 
respectively, in well-trained distance 
runners who consumed 9-mg/kg body 
weight (BW) caffeine orally 60-min prior to 
testing. Similarly, 6-mg/kg BW caffeine 
increased ET in a sample of healthy active 
males by 22% at 80-85% VO2MAX when 
orally ingested 90-min before testing (15).  
Other studies have shown increases in ET 
by 19.5% (10), 26.9-30.0% (27), and 27% (25).  
In contrast, Hendrix et al. (19) found that a 
caffeine-containing supplement with 400-
mg (~5-mg/kg BW) caffeine, 66.7-mg 
capsicum extract, 10-mg bioperine, and 40-
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mg niacin elicited no statistical 
improvement for ET.  Unlike the 
aforementioned studies, the authors used 
an untrained sample and a cycle TTE 
intensity that corresponded to 80% power 
output of max power elicited at VO2MAX 
(WMAX).  In a different sample of untrained 
participants, 5-mg/kg BW caffeine was 
orally ingested 60-min prior to cycle TTE at 
10% WMAX above and below anaerobic 
threshold (11).  A statistical increase in 
performance was seen below the anaerobic 
threshold while no difference was seen 
above the anaerobic threshold for ET.  
Accordingly, no improvement found by 
Hendrix et al. (19) may be due to an 
increased reliance on anaerobic energy 
systems elicited by the TTE test’s high 
intensity relative to an untrained 
population. 
 
Unlike endurance tests, caffeine has shown 
no evidence supporting an ergogenic effect 
for the 30-s Wingate (WIN) test between 
caffeine and placebo conditions.  No 
statistical differences for peak power (PP) 
have been seen in resistance-trained men 
(3), recreationally active men (16,17,22), 
healthy men (6), or healthy men and 
women (9).  Mean power (MP) and fatigue 
index (FI) were not significantly different in 
recreationally active men (16,17,22).   
Similarly, MP was not significantly 
different in resistance trained men (3).  
Notably, the aforementioned studies used 
flywheel resistances of 0.075-0.090-kg/kg 
BW and varied caffeine dosages (~2.4-
mg/kg BW to 6-mg/kg BW). 
 
Repeated-sprint (RS) performance in single 
and multiple sets has apparently benefitted 
from caffeine use as measured by several 
dependent variables, including total sprint 
(TS) and mean sprint (MS) times for a given 
set of sprints, fastest sprint (FS), and the 
difference between initial and final sprints 
(∆IF).  Carr et al. (8) showed statistically 
decreased TS when 6-mg/kg BW caffeine 
was orally ingested 60-min prior to 5-sets of 
6-reps of 20-m sprints repeated at 25-s (sets 
1, 3, and 5) or 60-s (sets 2 and 4) intervals.  
Similarly, Glaister et al. (13) showed 
decreased FS time by 0.06 ± 0.05-s for 12-
reps of 30-m sprints repeated at 35-s 
intervals with 5-mg/kg BW caffeine.  
Contradictory to these results, 6-mg/kg BW 
caffeine appeared to have no effect on MS 
(0.1% [-1.7-1.5%]) and ∆IF (0.7% [-1.8-3.2%]) 
for 10-reps of 20-m sprints at 10-s intervals 
(26).  It should be noted that the 
improvements seen by Carr et al. (8) and 
Glaister et al. (13) may be attributed to 
longer rest intervals of 20-55-s between 
repetitions as opposed to the ~6-s rest 
intervals utilized by Paton et al. (26). 
 
Beck et al. (3) reported a statistically 
significant 2.1% increase in one repetition 
maximum (1-RM) bench press (BP) in 37 
resistance trained men following ingestion 
of a caffeine-containing supplement 60-min 
prior to testing.  The supplement consisted 
of 201-mg caffeine, vitamin C and B6, 
niacin, pantothenic acid, and a variety of 
caffeine containing extracts. More recently, 
no significant difference was found 
between the same caffeine-containing 
supplement and placebo in untrained men 
for 1-RM BP (2).  This contradicted their 
previous study leading the authors to 
conclude that untrained participants may 
not receive the ergogenic effect of the 
caffeine-containing supplement while those 
in a trained state may.  Additionally, the 
latter finding is in line with recent reports 
of unaffected 1-RM BP in resistance trained 
(1) and untrained (19) men after oral 
consumption of 6-mg/kg BW and 400-mg 
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(~5-mg/kg BW) caffeine, respectively. Also, 
statistically insignificant differences 
between oral caffeine and placebo 
conditions were found for 1-RM leg 
extension (3,19) and leg press (1). 
  
Side Effects of Orally Ingested Caffeine 
Caffeine reportedly elicits an array of 
positive and negative side effects.  In a well 
written review, Fredholm et al. (12) stated 
that positive side effects of caffeine include 
participants claiming to be more active, 
attentive, and less fatigued.  Negative side 
effects include jitters, nervousness, anxiety 
(12), dizziness, headaches, muscle tremors, 
hunger sensations, insomnia, diuresis (25), 
and nausea (15).  Astorino et al. (1) found 
that 60% of participants reported negative 
side effects of tremor, insomnia, increased 
heart rate, and restlessness when a caffeine 
condition of 6-mg/kg BW caffeine orally 
ingested 60-min prior to exercise was 
received in opposition to a placebo 
condition.  The authors reported that these 
effects were more common in non-habitual 
caffeine users than habitual caffeine users 
and is in agreement with the review of 
Fredholm et al.  Fredholm et al. stated that 
non-habitual caffeine users may experience 
negative side effects of caffeine at all 
dosages, while habitual caffeine users 
typically experience negative side effects at 
large dosages.  Two of eight participants 
complained of nausea after oral ingestion of 
6-mg/kg BW caffeine (15).  This supports 
the data of Hudson et al. (20), who found 
that stomach distress, accompanied by 
restlessness and tremors, was statistically 
higher in the 6-mg/kg BW caffeine than 
placebo condition.  The aforementioned 
studies used 300-mg (4-mg/kg BW for a 75-
kg participant) to 6-mg/kg BW oral caffeine 
with stomach discomfort occurring in the 
latter dose.  The latter dose was within the 
5-9-mg/kg BW caffeine range needed to 
produce an ergogenic effect for cycle TTE 
and RS.  Therefore, taking oral caffeine to 
improve exercise performance (i.e. large 
dosages) may lead to undesirable stomach 
discomfort in both non-habitual and 
habitual users. 
 
Transdermal Application 
Studies have investigated transdermal 
kinetics of caffeine; however, no studies to 
our knowledge have done so solely with 
large quantities of caffeine, i.e. 75-mg 
caffeine applied topically.  Heard et al. (18) 
conducted an in vitro study of permeation 
of the caffeine containing extract guarana 
using full thickness porcine ear skin in 
accordance with the work of Meyer et al. 
(23).  The authors showed that increasing 
the amount of topically applied guarana 
extract, containing 2.1-6.0% caffeine, within 
a transdermal patch linearly increased (r2 = 
0.978) the rate of caffeine permeation.  This 
suggests that transdermal delivery of 
caffeine may have a dose-response 
relationship, possibly due to an altered 
electrochemical gradient.  When 10- g 
caffeine was applied to a skin surface area 
of 25-cm2, Otberg et al. (24) found that 
caffeine permeated the skin within 5-min 
and reached maximum plasma 
concentrations of 11.75-ng/mL at 60-min in 
vivo.  The plasma caffeine concentration of 
11.75-ng/mL for topically applied caffeine 
was much less than the plasma caffeine 
concentrations of 5.09-6.39- µg/mL (5) and 
6.85-µg/mL (21) shown to elicit an 
ergogenic effect for cycle TTE (4-6-mg/kg 
BW caffeine orally administered 60-90-min 
prior to analysis).  With a linear increase of 
plasma caffeine concentrations with 
increasing topically applied caffeine, a 
dosage three magnitudes greater (i.e. mg of 
caffeine) has a potential to produce plasma 
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concentrations three magnitudes greater 
(i.e. µg/mL caffeine).  Therefore, a 
relatively large dose of topically applied 
caffeine 60-min prior to exercise may be 
effective in delivering the quantity of 
caffeine necessary for an ergogenic effect to 
take place. 
 
The introduction of a caffeine-containing 
energy patch (EnP) may represent an 
option to supplement with caffeine to 
improve exercise performance while 
potentially avoiding the negative side effect 
of stomach discomfort associated with 
orally ingested caffeine.  Therefore, the 
purpose of this study was to investigate the 
effects of a caffeine-containing transdermal 
EnP on exercise performance in four well-
documented tests.    
 
METHODS 
 
Participants 
Three separate voluntary sample 
populations (see Table 1) were used to 
determine the effectiveness of EnP use on 1) 
cycle TTE, 2) WIN, and 3) RS and 1-RM BP.  
Prior to recruitment, the study was 
approved by Eastern Washington 
University’s Institutional Review Board.  
All participants were provided written and 
verbal instructions 48-h prior to testing and 
gave written consent.  Selection criterion 
required participants to be between the 
ages of 18 and 35-y and moderately active 
(i.e. 30-min of moderate intensity exercise 3-
5-d/wk).  Participants completed a 
standard AHA/ACSM preparticipation 
screening questionnaire to assess several 
risk factors.  Individuals with zero or one 
risk factor were allowed to participate in 
the present study.  Individuals with two 
risk factors were referred to a physician for 
clearance.  Individuals with three or more 
risk factors were not allowed to participate 
in the study.  Participants filled out a 
caffeine questionnaire to determine daily 
habitual caffeine use. 
 
Table 1.  Participant demographics and daily habitual 
caffeine use for the three samples. 
Sample  Age 
 (y) 
Height 
 (m) 
Weight  
(kg) 
Caffeine Use 
(mg/d) 
Cycle 
TTE 
 
n = 9 25 ± 4.7 1.74 ± 0.09 74.7 ± 18.7 171.6 ± 163.7 
WIN n = 13 22 ± 3.4 1.76 ± 0.06 89.5 ± 23.3 93.4 ± 146.8  
RS and  
1-RM BP 
n = 10 23 ± 5.0 1.71 ± 0.06 73.6 ± 10.2 179.5 ±190.3 
Values are presented as mean ± standard deviation.  
TTE = time-to-exhaustion, WIN = Wingate, RS = 
repeated-sprints, 1-RM = one repetition maximum, BP 
= bench press. 
 
Protocol 
The pre-experimental procedures were 
identical for each test.  Prior to arrival, all 
participants were asked to refrain from 
strenuous exercise, obtain a restful night’s 
sleep, remain well hydrated, and eat a 
regular meal.  Furthermore, participants 
were provided a list of caffeine-containing 
food stuffs and were told to refrain from 
caffeine consumption 48-h prior to testing.  
Upon arrival of the participants’ first 
session height, weight, and age were 
collected.  A minimum of 48-h separated 
each test session.  All participants 
underwent two tests, one with two EnP 
(Enceutical Corp., Addison, Texas) and one 
with two placebo patches (PlP).  Each EnP 
contained 37-mg caffeine, 5- g taurine, 5-
 g glucuronolactone, 4-mg green tea 
extract, 2-mg of both vitamin B3 and B5, 
and 800- g of both vitamin B6 and B12 
with a surface area of 14.5-cm2.  The 
amount of caffeine delivered topically with 
the EnP is reported in Table 2.  The PlP 
were previously exhausted EnP with spray 
adhesive applied. 
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Table 2.  Absolute and relative caffeine dosages for the 
three samples. 
Sample Caffeine  
(mg) 
Caffeine  
(mg/kg) 
Caffeine  
(mg/cm2) 
Caffeine  
(mg/kg/cm2) 
Cycle  
TTE 
74.0 1.030 ± 0.178    2.55 0.0355 ± 0.0061 
WIN 74.0 0.883 ± 0.225    2.55 0.0304 ± 0.0077 
RS and  
1-RM BP 
74.0 1.022 ±  0.129   2.55 0.0352 ± 0.0044 
Values expressed as mean ± standard deviation.  TTE = 
time-to-exhaustion, WIN = Wingate, RS = repeated-sprints, 
1-RM = one repetition maximum, BP = bench press.  
Caffeine dose is represented as an absolute value (mg) and 
relative to BW (mg/kg), surface area of the patch 
(mg/cm2), and both BW and surface area (mg/kg/cm2). 
 
Cycle TTE Experimental Procedures 
The cycle TTE tests were completed in four 
sessions.  For each cycle test, participants 
warmed up at a self-selected workload and 
duration and were required to maintain a 
pedal cadence of 60-65-rpm.  Seat height 
was recorded and used for each successive 
cycle test.  Session one consisted of an 
incremental workload test on a Monark 
328e cycle ergometer (Monark, Stockholm, 
Sweden) to determine relative VO2MAX 
(rVO2MAX).  For the first half of session two, 
the workload associated with 80% of 
rVO2MAX was verified with an Oxycon Pro 
mobile metabolic cart (CareFusion, San 
Diego, CA) during approximately 5-min of 
cycling. The second half of session two was 
devoted to test familiarization.  Participants 
were instructed to cycle to volitional 
exhaustion at the workload associated with 
80% of rVO2MAX using a cadence of 60-65-
rev/min.  If the cadence fell below 60-
rev/min, the participant received verbal 
encouragement to increase their cadence.  
When cadence fell below 60-rev/min for 
five continuous seconds, the test was 
terminated and the time in seconds was 
recorded.  Sessions three and four were the 
experimental TTE tests.  Two EnP or PlP 
were randomly assigned in a single-
blinded, crossover design for session three; 
session four received the opposite 
condition.  The patches were applied 
directly to the skin, proximal to the medial 
aspect of the belly of the right biceps 
brachii.  Following receipt of the EnP or 
PlP, participants rested for 60-min to allow 
for caffeine absorption.  During this time, 
no food, drinks, or other ergogenic aids 
were allowed except water as requested.  
The cycle TTE tests then commenced and 
were identical to the familiarization cycle 
TTE procedures. In addition, participants 
were blinded to all display feedback except 
cadence.  Time at exhaustion was recorded 
for data analysis. 
 
Wingate Experimental Procedures 
The WIN test is a 30-s maximal effort cycle 
ergometer test designed to assess anaerobic 
work capacity of an individual.  The WIN 
tests were completed in three sessions.  For 
each WIN test, participants warmed up at a 
self-selected workload and duration.  All 
tests were conducted on a Monark 894e 
cycle ergometer (Monark, Stockholm, 
Sweden).  Seat height was fitted to the 
participants’ comfort, recorded, and used 
for all successive WIN tests.  Session one 
was dedicated to familiarization.  
Participants performed a WIN with a 
resistance equivalent to 0.075-kg/kg BW 
and received strong verbal encouragement 
for the entire 30-s.  Sessions two and three 
were the experimental WIN tests.  Two EnP 
or PlP were randomly assigned in a single-
blinded, crossover design for session two; 
session three received the opposite 
condition.  The patches were applied 
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directly to the skin as previously described.  
Participants then rested for 60-min to allow 
for absorption.  During this time, no food, 
drinks, or other ergogenic aids were 
allowed except water ad libitum.  After the 
rest period, the WIN tests were performed.  
Mean power, PP, and FI were recorded for 
data analysis. 
 
One-RM and RS Experimental Procedures 
One-RM and RS were tested over a three 
session period.  A standard Olympic 
barbell, weights, and bench were used for 
BP testing.  The first session was a 
familiarization session.  Participants 
performed a BP warm-up that consisted of 
2-3-sets of 3-10-reps of increasing 
resistance.  Participants then attempted 
their estimated 1-RM BP weight.  If 
participants successfully lifted the weight, 
2-5-min rest was allotted and additional 
weight was added.  If the attempt was 
unsuccessful, rest was given and the weight 
was reduced.  In both cases, participants 
performed multiple 1-RM attempts until an 
accurate 1-RM was determined. Following 
the 1-RM BP test, participants relocated to 
an indoor 200-m synthetic track to perform 
the RS familiarization test.  Participants 
performed a warm-up including assigned 
and self-selected components  followed by 
6-reps of 20-y sprints with 30-s rest.  
Participants were told to complete each 
sprint at an all out maximal effort.  Sprint 
time was recorded using a wireless timing 
gate system (TC system, Brower Timing 
Systems, Draper, UT).  Sessions two and 
three were the experimental RS and 1-RM 
BP tests.  Two EnP or PP were randomly 
assigned in a single-blinded, crossover 
design for session two; session three 
received the opposite condition.  The 
patches were applied directly to the skin in 
the aforementioned manner.  Participants 
then rested for 60-min to allow for caffeine 
absorption.  During this time, no food, 
drinks, or other ergogenic aids were 
allowed except water ad libitum.  The 
weight pressed (WP) during the 1-RM BP 
and sprint times were recorded for data 
analysis. 
 
Statistical Analysis 
Paired t-tests were used to determine 
significant differences (p ≤ 0.05) between 
EnP and PlP conditions for ET (cycle TTE 
test), MP, PP, and FI (WIN test), MS and FS 
(RS test), and WP (1-RM BP test).  A two-
way repeated measures (condition x sprint) 
ANOVA was used to determine significant 
differences (p ≤ 0.05) between each of the 
six sprints for RS tests. Final sprint 
subtracted from the initial sprint 
determined ∆IF scores.  The difference 
between conditions (p ≤ 0.05) for ∆IF was 
determined using a paired t-test.  Lastly, to 
determine if there was a learning effect 
during testing for each exercise condition, 
the first and second tests were compared 
using t-tests for each of the aforementioned 
dependent variables. 
 
RESULTS 
There was no statistical difference (p = 0.25) 
between EnP and PlP ET despite there 
being a shorter ET in the EnP condition 
than the PlP condition (1627.4 ± 784.1-s v. 
2037.0 ± 1328.0-s, respectively).  Also, no 
learning effect (first test = 1769.7 ± 814.1-s, 
second test = 1810.3 ±1363.6-s, p = 0.91) was 
observed. 
 
Wingate results are presented in Table 3.  
Mean power for the EnP was less than the 
PlP, but was not statistically different (p = 
0.4).  The EnP was significantly less than 
the PlP for peak power by 3.00% (p = 0.04), 
or 23.1-W.  Additionally, EnP FI was less 
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than PlP FI; however, no statistical 
difference was found (p = 0.1).  
Furthermore, no learning effect was 
observed for MP (first test = 574.0 ± 184.2-
W, second test = 575.8-W ± 183.9, p = 0.77), 
PP (first test = 760.4 ± 251.1-W, second test 
= 760.7 ± 257.7-W, p = 0.98), or FI (first test = 
41.5 ± 7.1%, second test = 42.8 ± 7.2%, p = 
0.54). 
 
Table 3.  Power and fatigue results for the Wingate 
test. 
 MP (W) PP (W) * FI (%) 
EnP 572.5 ± 187.8 749.0 ± 256.1 40.5 ± 8.9 
PlP 577.2 ± 180.1 772.2 ± 252.1 43.8 ± 4.2 
Values are represented as mean ± standard 
deviation.  EnP = energy patch, PlP = placebo patch, 
MP = mean power, PP = peak power, FI = fatigue 
index.  * indicates significant difference between EnP 
and PlP conditions. 
No differences were seen between 
individual sprints (p > 0.05; see Figure 1).  
Mean sprint (p = 0.73), FS (p = 0.39), and ∆IF 
(p = 0.68) times were similar between EnP 
and PlP conditions (see Table 4).  
Furthermore, no learning effects were 
observed between individual sprints (p > 
0.05), MS (first test = 3.74 ±1.08-s, second 
test = 3.75 ± 1.08-s, p = 0.76), FS (first test = 
3.66 ± 0.28-s, second test = 3.67 ± 0.32, p = 
0.80), and ∆IF (first test = 0.023 ± 0.104-s, 
second test = 0.035 ± 0.081-s, p = 0.79). 
 
DISCUSSION 
The present study was novel because it was 
the first to investigate a topically applied 
EnP on aerobic and anaerobic performance.  
The EnP elicited no beneficial effects for 
any measured dependent variable for cycle 
TTE, WIN, RS, or 1-RM BP.  More than 
anything else, these results may be 
attributed to the caffeine dosage used.  We 
are inclined to believe that the topically 
applied dose of caffeine was too low to 
elucidate an ergogenic effect based on what 
has been previously reported in studies that 
administered caffeine orally.  However, it is 
difficult to compare the present results with 
those seen in previous studies because 
topically applied caffeine has different 
delivery kinetics than oral caffeine.  
Therefore, despite the fact that the EnP 
caffeine dosages were less than those 
reported for orally ingested caffeine, the 
dosages cannot be directly compared. 
 
 
 
Figure 1. Repeated sprint times showed no 
differences between conditions or successive sprints.  
PlP = placebo patch, EnP = energy patch. 
 
 
Table 4.  Sprint and fatigue results for the repeated-
sprint test. 
 MS (s) FS (s) ∆IF (s) 
EnP 3.74 ± 0.31 3.65 ± 0.31 0.020 ± 0.078 
PlP 3.75 ± 0.28 3.68 ± 0.29 0.038 ± 0.106 
Values are represented as mean ± standard 
deviation.  EnP = energy patch, PlP = placebo patch, 
MS = mean sprint, FS = fastest sprint, ∆IF = 
difference between initial and final sprints. 
 
ENERGY PATCH USE ON EXERCISE PERFORMANCE 
International Journal of Exercise Science                         148                                           http://www.intjexersci.com 
One-RM BP 
The present study observed no difference 
between conditions for 1-RM BP, which 
was expected based upon previous research 
(1,2,19).   
 
Wingate 
The WIN showed no significant differences 
for MP and FI across EnP and PlP 
conditions.  This is consistent with the 
literature for oral caffeine dosages of ~2.4-6-
mg/kg BW (2,3,9,16,22).  The EnP resulted 
in a significant decrease of 3.00% in PP 
despite the absence of a learning effect.  
This is in contrast to the aforementioned 
studies that showed no difference between 
caffeine and placebo conditions.  However, 
the significant difference observed in PP is 
likely a Type II error due to a low observed 
statistical power (0.035) associated with 
small sample size (n = 13) and small effect 
size (d = 0.09). 
 
Repeated-Sprints 
Repeated-sprints showed no difference 
between any of the measured dependent 
variables. The results of the present study 
disagreed with Carr et al. (8) and Glaister et 
al. (13) for MS and FS and agreed with 
Paton et al. (26) for FS and ∆IF.  The present 
study gave 30-s rest between sprints.  
Methodologically, this was more similar to 
Carr et al. (8) and Glaister et al. (13) who 
utilized ~20-55-s and dissimilar to Paton 
who gave ~6-s rest between sprints.  
Consequently, we believe this supports the 
assertion that too little caffeine was used in 
the present study.  If too little caffeine was 
used, plasma caffeine concentration levels 
would not have been elevated sufficiently 
to elicit an ergogenic effect.   Therefore, the 
74-mg dose of topically applied caffeine 
appeared to be equivalent to an orally-
ingested dose less than 5-mg/kg BW. 
 
Cycle TTE 
Exhaustion time showed no difference 
between EnP and PlP conditions.  Previous 
research has shown ET to increase with oral 
caffeine doses of 5-9-mg/kg BW.  As 
aforementioned, the lack of an ergogenic 
effect in the present study suggested that 
the 74-mg topical caffeine dose was 
equivalent to an oral dose less than 5-9-
mg/kg BW.  Furthermore, oral caffeine 
doses as low as 2-3-mg/kg BW have been 
shown to improve endurance performance 
while doses below 2-mg/kg BW have 
shown no effect (7).  In this case, the 
equivalent EnP caffeine dose may have 
even been less than the observed lower 
limits of 2-3-mg/kg BW.  
 
Statistical Considerations 
A subject in the cycle TTE test may have 
been an outlier.  This subject had a PlP ET 
of 5237-s and an EnP ET of 2938-s.  
Furthermore, EnP preceded PlP in test 
order.  When the t-test was recalculated 
omitting subject A, there was a greater 
probability that the EnP had no effect on ET 
(p = 0.53).  In addition to a possible outlier, 
the sample sizes of the three samples were 
less than or equal to 13.  These small sample 
sizes may have lowered the statistical 
power.  Therefore, in addition to a small 
topically applied caffeine dosage, the 
results of the study may have been 
compromised by a combination of small 
sample sizes, low effect sizes, and/or low 
statistical power. 
 
Continual Caffeine Delivery 
Despite the lack of observed ergogenic 
effects in this study, one possible advantage 
of an EnP would be the continual 
administration of caffeine.  An oral dose of 
5-mg/kg BW caffeine has shown ergogenic 
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effects 6-h post-administration (4,5).  
Caffeine has first order biological half-life 
kinetics with a half-life of 5-h.  As such, 5-
mg/kg BW caffeine would likely reach an 
insignificant relative dosage of 2-mg/kg 
BW after 6.6-h:  
 
 
 
It would be unlikely for an ergogenic effect 
to take place after this time period.  If an 
ergogenically equivalent transdermal 
dosage were applied, the patch may 
continue to release caffeine during exercise 
and prolong the ergogenic effect by 
increasing blood caffeine concentration at a 
given time.  Furthermore, additional EnP 
applied after the initial dosage and rest 
period (whether transdermal or oral) may 
also increase blood caffeine concentration at 
a given time during exercise.  The 
individual would not have to stop to redose 
for a continued ergogenic effect.  Therefore, 
EnP may be beneficial for prolonged 
endurance performance or when the time of 
performance is uncertain.  
 
 
Application Limitations 
Additional factors such as the presence, 
quantity, and anatomy of hair follicles in 
the dermis, applied surface area, and 
adhesive properties of the patch may have 
affected the ability of caffeine to be 
delivered to the blood.  The presence of hair 
follicles, especially those that penetrate the 
dermis into the hypodermis such as those 
in the chest area, may be the most 
important factor for transdermal caffeine 
delivery.  Caffeine delivered via hair 
follicles, termed the follicular pathway, 
may account for up to 50.2-58.6% of 
caffeine’s delivery kinetics (24,28).  
Therefore, transdermal patch application on 
the chest instead of the upper arm is 
suggested for future research.  
Additionally, the relationship between 
patch surface area and caffeine 
concentration per surface area for differing 
adhesives should be investigated in large 
doses (i.e. mg caffeine vs.  g caffeine) to 
determine the best options for transdermal 
delivery.  Furthermore, future studies using 
caffeine patches should analyze blood 
caffeine concentrations in addition to 
exercise performance to allow comparison 
between transdermal and oral caffeine 
administration.   
 
Conclusion 
The present study’s dosage of caffeine 
within an EnP was insufficient to elicit an 
ergogenic effect for both aerobic and 
anaerobic exercise tests.  Due to small 
sample sizes in the present study, future 
research with larger samples is suggested to 
verify the absence of statistical significance.  
Also, a greater dose of topically applied 
caffeine may be needed for caffeine’s effect 
to be present.  Further research is needed to 
investigate the delivery kinetics of caffeine 
in large doses along with exercise tests 
measuring both performance and plasma 
caffeine concentration to allow for 
comparison to oral caffeine studies. 
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